secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001641172-25-000917
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma reports Q4 2024 net loss $5.9M ($0.54/share); cash $24M as pipeline advances
--------------------------------------------------------------------------------

- Net loss for Q4 2024 was $5.9M ($0.54 per share) vs $4.2M ($0.39) in Q4 2023; full year net loss $1.93/share vs $1.47.
- Cash, cash equivalents and marketable securities $24.0M as of Dec 31, 2024, down from $41.3M at Dec 31, 2023.
- HARMONIC trial lead-in cohort (LP-300) showed 86% clinical benefit rate and 43% ORR in never-smoker NSCLC; expansion cohort reinforcing trends.
- LP-184 received two FDA Fast Track Designations (GBM, TNBC) and three Rare Pediatric Disease Designations; Phase 1a on cohort 11.
- RADR platform surpassed 100B oncology data points; MD Anderson collaboration shows LP-184 synergy with anti-PD1 in TNBC preclinical models.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000164117225000917/0001641172-25-000917-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000164117225000917/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-000917

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer